<DOC>
	<DOCNO>NCT02964936</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety ASP1517 intermittently administer Erythropoiesis Stimulating Agent ( ESA ) -untreated non-dialysis chronic kidney disease patient anemia .</brief_summary>
	<brief_title>A Study Intermittent Oral Dosing ASP1517 ESA-untreated Chronic Kidney Disease Patients With Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Subjects diagnose nondialysis chronic kidney disease ( CKD ) consider require renal replacement therapy study period Mean subject 's two recent Hb value randomization Screening Period must &lt; 10.5 g/dL absolute difference ≤1.3 g/dL two value Either transferrin saturation ≥ 5 % serum ferritin ≥ 30 ng/mL Female subject must either : Be nonchildbearing potential : postmenopausal prior prescreening , document surgically sterile Or , childbearing potential , Agree try become pregnant study inform consent acquisition 28 day final study drug administration And negative urine pregnancy test prescreening And , heterosexually active , agree consistently use two form highly effective birth control ( least one must barrier method ) start prescreening throughout study period 28 day final study drug administration . Female subject must agree breastfeed start prescreening throughout study period , 28 day final study drug administration . Female subject must donate ovum start prescreening throughout study period , 28 day final study drug administration . Male subject female spouse/partners childbearing potential must use two form highly effective birth control ( least one must barrier method ) start prescreening continue throughout study period , 12 week final study drug administration Male subject must donate sperm start prescreening throughout study period , 12 week final study drug administration Concurrent retinal neovascular lesion require treatment macular edema require treatment Concurrent autoimmune disease inflammation could impact erythropoiesis History gastric/intestinal resection consider influential absorption drug gastrointestinal tract ( exclude resection gastric colon polyp ) concurrent gastroparesis Uncontrolled hypertension Concurrent congestive heart failure ( NYHA Class III high ) History hospitalization treatment stroke , myocardial infarction , pulmonary embolism within 12 week prescreening assessment Positive hepatitis B surface antigen ( HBsAg ) antihepatitis C virus ( HCV ) antibody prescreening assessment , positive human immunodeficiency virus ( HIV ) past test Concurrent form anemia renal anemia Having receive treatment ESA , protein anabolic hormone , testosterone enanthate , mepitiostane within 6 week prescreening assessment Aspartate Aminotransferase ( AST ) , Alanine Aminotransferase ( ALT ) total bilirubin great criterion , previous concurrent another serious liver disease prescreening assessment Previous current malignant tumor ( recurrence least 5 year eligible . ) Having undergone red blood transfusion and/or surgical procedure consider promote anemia within 4 week prescreening assessment Having undergone kidney transplantation History serious drug allergy include anaphylactic shock Having previous history treatment ASP1517 Participation another clinical study postmarketing clinical study ( include medical device ) within 12 week informed consent acquisition</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Anemia</keyword>
	<keyword>Non-dialysis chronic kidney disease</keyword>
	<keyword>Roxadustat</keyword>
	<keyword>ASP1517</keyword>
</DOC>